Career Development Program

甲状腺癌翻译研究人员的发展需要勤奋致力于 确定初级有才华的研究人员，并将这些人安排到一个 支持性环境，不仅提供甲状腺癌方面的重要专业知识，而且提供 作为导师。在甲状腺癌研究领域产生领导者的另一种方式是鼓励 成功的转化型科学家将他们的才华从其他领域重新集中到这一领域。职业生涯 这种甲状腺癌孢子的开发计划(CDP)是应用的重要组成部分 因为它提供了一种机制，鼓励优秀的初级科学家在这个领域建立职业生涯 并吸引来自其他学科的老牌研究人员的专业知识。对于这个专注于甲状腺癌的人来说 应用、资源(患者和研究资源)和指导的结合 俄亥俄州立大学(OSU)和MD安德森甘瑟中心(MDACC)提供了无与伦比的 环境使这些新的和初级的调查人员能够作为独立的研究人员取得成功，并 发展未来的职业，这将有助于在遏制这种恶性肿瘤发病率上升方面取得进展 并为那些患有局部和远处转移疾病的人开发新的治疗方法。 为此，CDP将资助有前途的年轻调查人员，或在某些情况下资助更资深的调查人员 从临床实践或其他领域重新定向的教员，为期2年，每年5万美元。我们会特别注意 在招聘不同背景的申请者时，应给予报酬。将向所有人征求申请 俄亥俄州立大学和MDACC的部门和中心。CDP领导层将对他们进行资格筛选，以 确保有资格的妇女和少数群体有足够的代表性。申请将根据以下因素进行评判 候选人的潜力、拟议研究的实力以及导师的适当性。 申请将由CDP委员会成员和最终资金进行评分和排序 向孢子指导委员会提出的建议。每个职位将提供为期一年的资金，并提供 第二年取决于令人满意的进展。在授予的过程中，孢子将提供 44.6%的国家发展计划资金，将与之相匹配的38.1%，17.3%由OSUCCC和 MDACC分别为。该计划的成功将取决于由该计划产生的科学的质量 获奖者，他们在获得外部同行评审资金方面的成功，他们在学术上的成功 进展，以及它们在学术界和甲状腺癌的翻译研究中的保留。 相关性(请参阅说明)： 职业发展计划(CDP)是这个甲状腺癌孢子的重要组成部分 申请和国家孢子计划，因为它将确保一批学术教职员工 受过专门培训的翻译科学家和临床医生，致力于发现和应用新的方法 了解慢性支气管炎患者的病因和流行病学，预防、诊断、治疗和治疗 甲状腺癌。

The development of translational researchers in thyroid cancer requires a diligent commitment to the identification of talented researchers at the junior level, and the placement pf these individuals into a supportive environment which provides not only significant expertise in thyroid cancer, but also the provision for mentorship. Another way to produce leaders in the field of thyroid cancer research is to encourage successful translational scientists to re-focus their talents from other areas into this area. The Career Development Program (CDP) of this thyroid cancer SPORE is an essential component of the application because it provides the mechanism to encourage excellent junior scientists to establish careers in this field and to attract the expertise of established researchers from other disciplines. For this thyroid cancer-focused application, the combination of resources (both patient and research resources) and guidance present at The Ohio State University (OSU) and at the MD Anderson Gancer Center (MDACC) provides an unparalleled environment to enable these new and junior investigators to succeed as independent researchers and to develop future careers which will contribute to progress in stemming the rising incidence of this malignancy and develop new therapies for those with local and distant metastatic disease. To this end, the CDP will fund promising young investigators or, in certain circumstances, more senior faculty reorienting from clinical practice or another field for 2 years at $50,000 per year. Special attention will be paid to the recruitment of applicants from diverse backgrounds. Applications will be solicited from all departments and centers at OSU and MDACC. They will be screened for eligibility by CDP Leadership to assure adequate representation from qualified women and minorities. Applications will be judged based on the potential of the candidate, the strength of the proposed research and the appropriateness of the mentor. Applications will be scored and ranked by members of the CDP Committee and final funding recommendations made to the SPORE Steering Committee. Each position will be funded for one year, with a second year dependent upon satisfactory progress. Over the course of the grant, the SPORE will provide 44.6% of the funding for the CPD, which will be matched by 38.1%, and 17.3% provided from OSUCCC and MDACC, respectively. Success of the program will be judged by the quality of the science generated by the awardees, their success in obtaining external peer-reviewed funding, their success in academic advancement, and their retention in academia and translational research in thyroid cancer. RELEVANCE (See instructions): The Career Development Program (CDP) is an important component of this thyroid cancer SPORE application and the national SPORE program because it will assure a cadre of academic faculty who are specially trained translational scientists and clinicians dedicated to discover and apply new approaches to understanding the etiology and epidemiology, prevention, diagnosis, treatment and cure of patients with thyroid cancer.